Muscle Loss: When to See a Doctor

What Is Muscle Loss and Why Does It Happen?

Muscle loss exists on a spectrum from the slow, age-related decline called sarcopenia to the aggressive wasting seen in cancer cachexia. Understanding where a patient falls on that spectrum changes the urgency of treatment and the choice of interventions.

The Biology Behind Muscle Wasting

Skeletal muscle is in constant turnover. Protein synthesis and protein breakdown must stay balanced. When breakdown outpaces synthesis, net muscle mass falls. The primary drivers of that imbalance include declining anabolic hormones (testosterone, growth hormone, IGF-1), elevated pro-inflammatory cytokines such as TNF-alpha and IL-6, inadequate dietary protein, and disuse 1.

After age 30, muscle mass drops roughly 3 to 8% per decade, accelerating to 1 to 2% per year after age 60 2. That slow background decline becomes clinically significant when it crosses thresholds that impair function, raise fall risk, or signal underlying disease.

Sarcopenia vs. Cachexia vs. Atrophy

These three terms describe different mechanisms.

• Sarcopenia is age-related, driven primarily by hormonal changes, inactivity, and inadequate protein intake.
• Cachexia is inflammation-driven wasting linked to cancer, heart failure, HIV, or severe chronic kidney disease. Cachexia causes involuntary weight loss of more than 5% in 12 months alongside fatigue, weakness, and anorexia 3.
• Disuse atrophy follows immobility, bed rest, or limb casting and is reversible with reloading.

Getting the diagnosis right matters because the treatments differ substantially.

Common Causes of Muscle Loss

Muscle loss rarely has one cause. Most patients have two or three contributing factors operating at the same time.

Age and Hormonal Decline

Testosterone in men drops roughly 1 to 2% per year after age 30 4. Low testosterone independently predicts lower appendicular lean mass and greater functional decline. A 2006 analysis in the Journal of Clinical Endocrinology and Metabolism found that men in the lowest testosterone quartile lost significantly more lean mass over 4.5 years than men in the highest quartile 4.

Estrogen decline in peri- and postmenopausal women similarly accelerates muscle protein breakdown. Women can lose up to 2% of muscle mass per year in the 3 years surrounding menopause 5.

Inadequate Protein Intake

The Recommended Dietary Allowance of 0.8 g protein per kg body weight was set to prevent deficiency, not to preserve muscle mass in older adults. Current evidence supports 1.2 to 1.6 g/kg/day for adults trying to maintain or rebuild muscle, particularly those over 50 6. Many older adults consume well below that threshold.

Chronic Disease

Several conditions drive muscle wasting through systemic inflammation:

• Cancer (cachexia affects 50 to 80% of cancer patients and contributes to 20 to 30% of cancer deaths) 3
• Type 2 diabetes (insulin resistance impairs muscle protein synthesis)
• Chronic kidney disease (metabolic acidosis accelerates protein catabolism)
• Heart failure (reduced cardiac output limits oxygen and nutrient delivery to muscle)
• COPD (systemic inflammation plus corticosteroid use)

Physical Inactivity and Bed Rest

Five to seven days of complete bed rest can reduce muscle protein synthesis by 30% and cause measurable strength loss 7. Even sustained low activity without outright bed rest, sitting for more than 8 to 10 hours per day, predicts accelerated lean mass loss in prospective cohort data.

Medications

Some medications directly or indirectly reduce muscle mass:

• Corticosteroids at doses above 7.5 mg prednisone daily for more than 3 months cause clinically significant myopathy
• GLP-1 receptor agonists (semaglutide, tirzepatide): trial data show approximately 39% of weight lost during semaglutide 2.4 mg therapy in STEP-1 came from lean mass when resistance training was not part of the protocol 8
• Statins produce myopathy in roughly 5 to 10% of users, though severe rhabdomyolysis occurs in fewer than 1 in 10,000 9
• Androgen deprivation therapy for prostate cancer reduces lean mass by roughly 2 to 3% in the first year 10

When Should You Worry About Muscle Loss?

Not every muscle change demands urgent care. These specific signs and scenarios should prompt a physician visit within days to weeks, not months.

Red Flags That Need Prompt Evaluation

See a doctor soon if you notice:

• Unintentional weight loss exceeding 5% of body weight over 6 to 12 months
• Visible muscle wasting in one limb without a clear injury
• Rapid weakness developing over days to weeks (not months)
• Difficulty swallowing alongside muscle weakness (suggests neuromuscular disease)
• Muscle pain, dark urine, or severe cramping (may indicate rhabdomyolysis)
• Weakness accompanied by skin changes, hair loss, or cold intolerance (thyroid or autoimmune cause)

The European Working Group on Sarcopenia in Older People (EWGSOP2) 2018 consensus states: "Low muscle strength is currently the most reliable indicator of sarcopenia and is strongly predictive of adverse outcomes, more so than low muscle quantity alone." 11

Age-Related Decline vs. Pathological Loss

Losing 1 to 2% of muscle mass per year after age 60 with preserved function is expected. Losing that same amount in 3 months is not. Speed matters as much as magnitude. A patient who drops two pants sizes in a belt-notch over 8 weeks deserves investigation regardless of age.

Functional Thresholds That Signal Risk

The EWGSOP2 guideline uses specific cut-points to flag clinical concern 11:

• Grip strength: below 27 kg in men, below 16 kg in women
• 5-times chair-stand test: more than 15 seconds
• Gait speed: below 0.8 m/s on a 4-meter walk test
• Short Physical Performance Battery (SPPB) score: 8 or below

Crossing any one threshold warrants measurement of muscle mass by DXA or bioelectrical impedance analysis to confirm the diagnosis.

How Is Muscle Loss Diagnosed?

Diagnosis involves three steps: identifying low muscle strength, confirming low muscle quantity, and determining the underlying cause.

Physical Tests and Questionnaires

The SARC-F questionnaire (strength, assistance walking, rising from a chair, climbing stairs, falls) has a sensitivity of roughly 21% and specificity of 92% for sarcopenia in older adults, making it a useful screening filter rather than a diagnostic tool 12. A positive SARC-F score of 4 or above should trigger objective testing.

Imaging and Body Composition

DXA (dual-energy X-ray absorptiometry) remains the most widely available method for measuring appendicular lean mass. An appendicular lean mass index (ALMI) below 7.0 kg/m2 in men and below 5.5 kg/m2 in women meets the EWGSOP2 threshold for low muscle mass 11.

CT and MRI provide higher precision and are used in research settings and in oncology to track cachexia. Bioelectrical impedance is less accurate but accessible in clinical offices.

Laboratory Workup

Blood tests help identify the underlying cause. A standard workup typically includes:

• Complete metabolic panel (kidney and liver function, glucose)
• Thyroid-stimulating hormone (hypothyroidism causes myopathy)
• Complete blood count (anemia, infection)
• Inflammatory markers: CRP, ESR
• Testosterone (total and free) in men; estradiol in peri/postmenopausal women
• IGF-1 (growth hormone axis)
• Vitamin D (25-OH): levels below 20 ng/mL are associated with lower muscle strength and higher fall risk 13
• Serum albumin and prealbumin (nutritional status)

For patients with focal weakness or rapid progression, electromyography (EMG) and nerve conduction studies help distinguish myopathy from neuropathy.

Treatment for Muscle Loss

Treatment is most effective when it addresses both the primary cause and the downstream mechanisms of protein breakdown.

Resistance Training: The Non-Negotiable Foundation

Progressive resistance training 2 to 3 times per week is the most evidence-backed intervention for sarcopenia and disuse atrophy. A 2017 Cochrane review of 121 trials found resistance training improved muscle strength (standardized mean difference 0.84, 95% CI 0.67 to 1.00) and physical performance in older adults 14. The effect is present even in adults over 80.

Starting loads can be low. What drives adaptation is progressive overload, meaning the load must increase over time as strength improves. Two sessions per week targeting all major muscle groups is a reasonable minimum.

Protein and Nutritional Targets

Protein intake of 1.2 to 1.6 g/kg/day distributed across 3 to 4 meals of 25 to 40 g each maximizes muscle protein synthesis in older adults 6. Leucine content per meal matters: at least 2.5 to 3 g of leucine per meal appears necessary to stimulate the mTORC1 pathway in aging muscle 15.

Creatine monohydrate supplementation at 3 to 5 g/day has shown additive benefit to resistance training in older adults in multiple meta-analyses, improving lean mass by approximately 1.37 kg more than training alone over 12 to 24 weeks 16.

Hormonal Interventions

Testosterone replacement therapy (TRT): A 2016 JAMA Internal Medicine meta-analysis of 52 randomized trials found testosterone therapy increased lean mass by a mean of 1.6 kg (95% CI 1.1 to 2.1 kg) and reduced fat mass compared with placebo in men with confirmed hypogonadism 17. TRT is appropriate when serum total testosterone is below 300 ng/dL on two morning measurements with consistent symptoms.

Vitamin D: Supplementation at 800 to 2,000 IU/day in adults with 25-OH levels below 20 ng/mL modestly improves muscle strength and reduces fall risk. A meta-analysis in the BMJ (N=26,000+) found vitamin D supplementation reduced fall risk by approximately 17% 18.

Growth hormone and IGF-1: Recombinant human growth hormone can increase lean mass but also increases adverse effects (edema, glucose intolerance, carpal tunnel). Current Endocrine Society guidelines do not recommend GH for sarcopenia outside of diagnosed adult growth hormone deficiency 19.

Managing Muscle Loss on GLP-1 Therapy

GLP-1 receptor agonists produce substantial weight loss but carry a real risk of lean mass reduction. In STEP-1 (N=1,961), participants on semaglutide 2.4 mg lost a mean 14.9% of body weight at 68 weeks vs. 2.4% on placebo 8. Body composition substudies suggest roughly 39% of that weight loss came from lean mass in participants not doing structured resistance training.

The practical implication: any patient starting a GLP-1 agonist should be counseled to begin a resistance training program and consume at least 1.2 g protein/kg/day from the first day of treatment. Some clinicians co-prescribe creatine monohydrate. In men with borderline-low testosterone who are starting GLP-1 therapy, checking testosterone levels before and 3 months after starting treatment may identify those who need concurrent TRT to preserve muscle.

Treating Cachexia

Disease-related cachexia requires treating the underlying condition first. For cancer cachexia specifically, megestrol acetate is FDA-approved for appetite stimulation and weight gain (at 800 mg/day it increases body weight but the gain is predominantly fat, not muscle) 20. Anamorelin, a ghrelin receptor agonist, increased lean mass by 1.10 kg vs. Placebo in the ROMANA 1 trial (N=484) in non-small cell lung cancer patients with cachexia 21. Anamorelin is approved in Japan and under FDA review in the United States.

Muscle Loss and Specific Populations

Postmenopausal Women

Estrogen directly supports muscle protein synthesis and satellite cell activity. After menopause, the rate of muscle loss accelerates and coincides with bone density decline, raising fracture risk from two directions at once. Hormone therapy (estradiol plus progesterone or progestin) has shown modest but real benefits for muscle mass in randomized data 5. The decision to use HRT for muscle preservation should be made with a full assessment of cardiovascular and breast cancer risk.

Men Over 50 with Symptoms

The intersection of low testosterone, physical inactivity, and excess adiposity creates a negative spiral: fat tissue aromatizes testosterone to estradiol, further lowering free testosterone, which reduces drive for physical activity and protein intake. Breaking that cycle often requires addressing two or three factors simultaneously. A morning serum total testosterone combined with a free testosterone measurement gives the clearest picture. The American Urological Association defines hypogonadism as a total testosterone below 300 ng/dL 22.

Adults Using Chronic Corticosteroids

Steroid-induced myopathy is dose- and duration-dependent. Prednisone at 7.5 mg/day for 6 months measurably reduces type II muscle fiber cross-sectional area. For patients on chronic steroids, a baseline ALMI measurement by DXA at 3 months and resistance training twice weekly should be standard care, not optional 23.

A Framework for Deciding When to Act

Three questions help a patient and clinician decide how urgently to act on muscle loss:

1. Speed: Is the loss happening over months (chronic, less urgent) or weeks (acute, investigate now)?
2. Function: Has the person fallen, lost the ability to rise from a chair unaided, or noticed grip weakness? Functional impairment moves the evaluation from routine to prompt.
3. Systemic symptoms: Weight loss, night sweats, fever, lymphadenopathy, or bone pain alongside muscle wasting warrant urgent workup for malignancy or systemic disease.

A patient who is 65, lost 6 lbs in 3 months, cannot complete a 5-times chair-stand test in under 15 seconds, and has a grip strength of 22 kg meets criteria for probable sarcopenia by EWGSOP2 and needs same-week evaluation, not reassurance.

A 40-year-old who notices less definition after 6 weeks of reduced gym attendance and lower protein intake does not have sarcopenia. That person needs a dietary and training review, not urgent investigation.